Will Sucampo acquisition mean PCP sales force loses Amitiza?

If decision truly has been made and the above post is legit and Takeda loses Ami, then I would think more voices will be put on Trin.

 

Trin needs more voices IMHO.

 

I’m sure we see some reps go to NSS but a lot of PC will be cut if this info is correct. BUT, The NSS reps around me always say they have trouble filling out the day because there isn’t enough places to go.

 

Critically evaluating the loss of Ami, let's be logical? It's a product at the end of it's cycle (what 2-3 years MAX); Mallinckrodt Pharmaceuticals is a tiny tiny company with hardly any presence with their sales force. Are they going to sever a good thing and abort a profitable contract? Really? They bought Sucampo for the R&D towards certain molecules and the future investment towards that endeavor..Could Ami be pulled from us? Sure anything is possible but my guess is no for now.